Starling Oncology (STLN) reported $503M in revenue for fiscal 2025, +27.8% year on year. That ranks #2202 by revenue among 2853 SEC filers and #215 in Healthcare. Net income was $60.6M, a net margin of 12.1%. Revenue has grown 21.8% a year on average since 2020 ($188M then). The fiscal 2025 balance sheet shows $165M in total assets, $33.6M in cash and $77.4M in long-term debt.
Scale corrected: the company's XBRL data reports net income (÷10³) without the scale factor (for example "4,801" for 4.8 billion). The figures are shown at the corrected scale; each links to the filing it comes from.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $503M | +27.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$36.1M | +$24.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $60.6M | −6.3% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$24.6M | +$2.0M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.2M | −15.5% | FY20252025-12-31 |
| Total assetsAssets | $165M | −4.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$15.7M | −$19.3M | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $33.6M | −32.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $77.4M | −16.9% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $147M | −$2.5M | Open → |
| Q2 20262026-06-30 | $161M | −$9.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Starling Oncology, Inc.
- Ticker
- STLN
- Exchange
- Nasdaq
- SIC classification
- Services-Offices & Clinics of Doctors of Medicine (8011)
- Fiscal year end
- 12-31
- CIK
- 0001799191
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KMar 12, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| InotivNOTVQ | $513M | −$68.6M |
| Adma BiologicsADMA | $510M | $147M |
| GlaukosGKOS | $507M | −$188M |
| Starling OncologySTLN | $503M | $60.6M |
| Bridgebio PharmaBBIO | $502M | −$733M |
| Ascend WellnessAAWH | $501M | −$118M |
| Travere TherapeuticsTVTX | $491M | −$25.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Starling Oncology — Key figures |url=https://companiesranked.com/en/company/starling-oncology |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Starling Oncology — Key figures. CompaniesRanked. https://companiesranked.com/en/company/starling-oncologyBibTeX
@misc{companiesranked-en-company-starling-oncology-2026,
author = {{CompaniesRanked}},
title = {{Starling Oncology — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/starling-oncology}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001799191-26-000007 · March 12, 2026
{{cite web |title=Starling Oncology — Key figures — 10-K (0001799191-26-000007) |url=https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.